Amgen AMGN delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The company has been recording consistently strong top-line performance. Amgen ...

--Amgen today announced new Repatha ® combined data from the Phase 3 FOURIER and FOURIER Open Label Extension studies and the Phase 2 OCEAN- DOSE study of investigational olpasiran, an siRNA that ...

(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...

"Amgen is pleased to present the results of OSLER-1, the longest study of a PCSK9 inhibitor to date, which clearly demonstrate the durable, long-term efficacy and safety of Repatha in reducing LDL-C ...

The company boasts a strong biosimilars portfolio and the business has become an increasingly important contributor to the ...

Matthew Herper covers medical innovation — both its promise and its perils. Amgen said Thursday that its cholesterol-lowering shot, Repatha, prevented a composite of heart disease death, heart attack, ...

Amgen’s (AMGN) worst-case scenario from the outcomes trial of Repatha can be dismissed. The California-based group says the cholesterol-lowering jab reduced risk of heart attacks, strokes and ...

Repatha’s withdrawal from Denmark is best understood as an early signal of the impact of Most Favored Nation drug pricing proposals in the US. When low-price foreign markets become linked to large U.S ...

Biogen BIIB and Amgen AMGN are two of the biggest biotech companies in the world. Amgen has a strong presence in the oncology ...